Abstract: Pharmaceutical compositions for the treatment of a viral infection by a type-A influenza virus are provided. The compositions include a compound having the property of acting as an inhibitor of the attachment of the viral RNA to the nucleoprotein of the type-A influenza virus, the compound having the property of binding to the binding domain of the viral RNA to the nucleoprotein. Methods of treating an infection by influenza virus by administering an effective amount of the compound to a subject are also disclosed. A process for identifying a compound having the property of binding to the binding domain of the viral RNA to the nucleoprotein of the type-A influenza viruses are further disclosed.

Abstract: A pharmaceutical composition for treating viral infections by an influenza type A virus, includes a compound capable of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, and capable of binding to the viral-RNA-binding domain on the nucleoprotein. A pharmaceutical composition for treating viral infections by an orthomyxovirus, includes a compound capable of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of orthomyxoviruses, and capable of binding to the viral-RNA-binding domain on the nucleoprotein of the viruses. A compound acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, and binding to the viral-RNA-binding domain on the nucleoprotein of influenza type A viruses and a method for identifying such a compound having these properties are also described.

Abstract: Described herein are topical pain compositions comprising between 15 and 90% mannitol, for use in the treatment of pain, itch and other cutaneous nerve conditions. The resulting compositions may be in the form of creams, gels, lotions, ointments, foams, suppositories, and sprays.

Abstract: Described herein are topical pain compositions comprising between 15 and 90% mannitol, for use in the treatment of pain, itch and other cutaneous nerve conditions. The resulting compositions may be in the form of creams, gels, lotions, ointments, foams, suppositories, and sprays.

Abstract: Described herein are topical pain compositions comprising between 15 and 90% mannitol, for use in the treatment of pain, itch and other cutaneous nerve conditions. The resulting compositions may be in the form of creams, gels, lotions, ointments, foams, suppositories, and sprays.

Abstract: Described herein are topical pain compositions comprising between 15 and 90% mannitol, for use in the treatment of pain, itch and other cutaneous nerve conditions. The resulting compositions may be in the form of creams, gels, lotions, ointments, foams, suppositories, and sprays.

Abstract: A pharmaceutical composition for treating viral infections by an influenza type A virus, includes a compound capable of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, and capable of binding to the viral-RNA-binding domain on the nucleoprotein. A pharmaceutical composition for treating viral infections by an orthomyxovirus, includes a compound capable of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of orthomyxoviruses, and capable of binding to the viral-RNA-binding domain on the nucleoprotein of the viruses. A compound acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, and binding to the viral-RNA-binding domain on the nucleoprotein of influenza type A viruses and a method for identifying such a compound having these properties are also described.

Abstract: A new and distinct Hydrangea cultivar named ‘INH-HYD-B4’ is disclosed, characterized by purple/bronze stems and young foliage, and a large inflorescence. The new variety is a Hydrangea, suitable for outdoor container and garden purposes.

Abstract: A new and distinct cultivar of Hydrangea plant named ‘FRENCH BOLERO’ is disclosed, characterized by a distinct combination of small, narrow foliage, and a flattened lacecap inflorescence composed of light pink flowers. Plants are sterile, begin flowering early and produce numerous thin stems. The new variety is a Hydrangea, normally produced as an ornamental plant for containers or gardens.